Mast cells protect from skin tumor development and limit tumor growth during cutaneous de novo carcinogenesis in a Kit-dependent mouse model

Experimental Dermatology

Volumn 23, Issue 3, 2014, Pages 159-164

  Siebenhaar, Frank ^a   Metz, Martin ^a   Maurer, Marcus ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Carcinogenesis; Inflammation; Mast cells

Indexed keywords

12 TETRADECANOYL PHORBOL 13 ACETAT; 7,12 DIMETHYLBENZ[A]ANTHRACENE; COCARCINOGEN; UNCLASSIFIED DRUG;

ADOPTIVE TRANSFER; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; B LYMPHOCYTE; CANCER INCIDENCE; CD8+ T LYMPHOCYTE; CELL HYPERPLASIA; CELL INFILTRATION; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; DERMATITIS; FEMALE; GRANULOCYTE; MAST CELL; MONOCYTE; MOUSE; NONHUMAN; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SKIN TUMOR; TUMOR GROWTH;

CARCINOGENESIS; INFLAMMATION; MAST CELLS;

9,10-DIMETHYL-1,2-BENZANTHRACENE; ADOPTIVE TRANSFER; ANIMALS; CARCINOGENESIS; CELL COUNT; CELL DEGRANULATION; CYTOPROTECTION; DISEASE MODELS, ANIMAL; FEMALE; GRANULOCYTES; MACROPHAGES; MAST CELLS; MICE; PROTO-ONCOGENE PROTEINS C-KIT; SKIN NEOPLASMS; TETRADECANOYLPHORBOL ACETATE; TUMOR BURDEN;

EID: 84897696931     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12328     Document Type: Article

References (56)

1. Frame S, Crombie R, Liddell J et al. Philos Trans R Soc Lond B Biol Sci 1998: 353: 839-845.
2. Littlepage L E, Egeblad M, Werb Z. Cancer Cell 2005: 7: 499-500.
3. Tanooka H, Kitamura Y, Sado T et al. J Natl Cancer Inst 1982: 69: 1305-1309.
4. Dimitriadou V, Koutsilieris M. Anticancer Res 1997: 17: 1541-1549.
5. Ch'ng S, Wallis R A, Yuan L et al. Mod Pathol 2006: 19: 149-159.
6. Wasiuk A, de Vries V C, Hartmann K et al. Clin Exp Immunol 2009: 155: 140-146.
7. Galli S J, Kalesnikoff J, Grimbaldeston M A et al. Annu Rev Immunol 2005: 23: 749-786.
8. Galli S J, Nakae S, Tsai M. Nat Immunol 2005: 6: 135-142.
9. Dawicki W, Marshall J S. Curr Opin Immunol 2007: 19: 31-38.
10. Metz M, Maurer M. Trends Immunol 2007: 28: 234-241.
11. Metz M, Siebenhaar F, Maurer M. Immunobiology 2008: 213: 251-260.
12. Kalesnikoff J, Galli S J. Nat Immunol 2008: 9: 1215-1223.
13. DiGiovanni J. Pharmacol Ther 1992: 54: 63-128.
14. Nakano T, Sonoda T, Hayashi C et al. J Exp Med 1985: 162: 1025-1043.
15. Galli S J, Kitamura Y. Am J Pathol 1987: 127: 191-198.
16. Siebenhaar F, Syska W, Weller K et al. Am J Pathol 2007: 170: 1910-1916.
17. Wershil B K, Murakami T, Galli S J. J Immunol (Baltimore, Md: 1950) 1988: 140: 2356-2360.
18. Maurer M, Lopez Kostka S, Siebenhaar F et al. Faseb J 2006: 20: 2460-2467.
19. Waskow C, Bartels S, Schlenner S M et al. Blood 2007: 109: 5363-5370.
20. von Stebut E. Eur J Dermatol 2007: 17: 115-122.
21. Yusuf N, Nasti T H, Katiyar S K et al. Cancer Res 2008: 68: 3924-3930.
22. Yusuf N, Timares L, Seibert M D et al. Toxicol Appl Pharmacol 2007: 224: 308-312.
23. Marshall J S, Jawdat D M. J Allergy Clin Immunol 2004: 114: 21-27.
24. Mekori Y A, Metcalfe D D. Immunol Rev 2000: 173: 131-140.
25. Yuspa S H. J Dermatol Sci 1998: 17: 1-7.
26. Fitzpatrick F A. Int Immunopharmacol 2001: 1: 1651-1667.
27. Moore R J, Owens D M, Stamp G et al. Nat Med 1999: 5: 828-831.
28. Weber A, Maurer M. Dermatology 2005: 211: 298-299.
29. von Stebut E, Metz M, Milon G et al. Blood 2003: 101: 210-215.
30. Weller K, Foitzik K, Paus R et al. Faseb J 2006: 20: 2366-2368.
31. Wulff B C, Wilgus T A. Exp Dermatol 2013: 22: 507-510.
32. Sinnamon M J, Carter K J, Sims L P et al. Carcinogenesis 2008: 29: 880-886.
33. Wedemeyer J, Galli S J. Lab Invest 2005: 85: 388-396.
34. Tanaka T, Ishikawa H. Semin Immunopathol 2013: 35: 245-254.
35. Coussens L M, Raymond W W, Bergers G et al. Genes Dev 1999: 13: 1382-1397.
36. Crivellato E, Nico B, Ribatti D. Cancer Lett 2008: 269: 1-6.
37. Ribatti D, Crivellato E. Adv Exp Med Biol 2011: 716: 270-288.
38. Daniel D, Meyer-Morse N, Bergsland E K et al. J Exp Med 2003: 197: 1017-1028.
39. Roberts S J, Ng B Y, Filler R B et al. Proc Natl Acad Sci U S A 2007: 104: 6770-6775.
40. Hedstrom G, Berglund M, Molin D et al. Br J Haematol 2007: 138: 68-71.
41. Artuc M, Guhl S, Babina M et al. Exp Dermatol 2011: 20: 1020-1022.
42. Gooch J L, Lee A V, Yee D. Cancer Res 1998: 58: 4199-4205.
43. Gordon J R, Galli S J. Nature 1990: 346: 274-276.
44. Theoharides T C, Conti P. Trends Immunol 2004: 25: 235-241.
45. Maher S G, Reynolds J V. Recent Results Cancer Res 2011: 185: 1-34.
46. Vendramini-Costa D B, Carvalho J E. Curr Pharm Des 2012: 18: 3831-3852.
47. Metz M, Grimbaldeston M A, Nakae S et al. Immunol Rev 2007: 217: 304-328.
48. Grimbaldeston M A, Nakae S, Kalesnikoff J et al. Nat Immunol 2007: 8: 1095-1104.
49. Maurer M, Wedemeyer J, Metz M et al. Nature 2004: 432: 512-516.
50. Metz M, Piliponsky A M, Chen C C et al. Science 2006: 313: 526-530.
51. Lilla J N, Chen C C, Mukai K et al. Blood 2011: 118: 6930-6938.
52. Reber L L, Marichal T, Galli S J. Trends Immunol 2012: 33: 613-625.
53. Feyerabend T B, Weiser A, Tietz A et al. Immunity 2011: 35: 832-844.
54. Scholten J, Hartmann K, Gerbaulet A et al. Transgenic Res 2008: 17: 307-315.
55. Antsiferova M, Martin C, Huber M et al. J Immunol (Baltimore, Md: 1950) 2013: 191: 6147-6155.
56. Reiners J J Jr, Nesnow S, Slaga T. J Carcinogenesis 1984: 5: 301-307.